RAFAEL HOLDINGS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period
RAFAEL HOLDINGS, INC. (RFL) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period of 99.43 thousand shares for the 3-month period ending 2025-10-31, per its 10-Q filed 2025-12-12.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod · last filed 2025-12-12
- RAFAEL HOLDINGS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2025-10-31 was 99.43K shares.
- RAFAEL HOLDINGS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2025-07-31 was 118.60K shares, a 25.42% decline year-over-year.
- RAFAEL HOLDINGS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2025-04-30 was 0.00 shares.
- RAFAEL HOLDINGS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for the quarter ending 2024-07-31 was 159.02K shares.
- RAFAEL HOLDINGS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2025 was 473.51K shares, a 6.57% decline from fiscal 2024.
- RAFAEL HOLDINGS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2024 was 506.83K shares, a 130.36% increase from fiscal 2023.
- RAFAEL HOLDINGS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2023 was 220.02K shares, a 85.65% decline from fiscal 2022.
- RAFAEL HOLDINGS, INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2022 was 1.53M shares, a 60.34% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 12 month |
|---|---|---|---|---|
| 2025-10-31 | 99.43K shares 10-Q · filed 2025-12-12 | 218.03K shares derived: sum of 2 quarters · filed 2025-12-12 | 218.03K shares derived: sum of 3 quarters · filed 2025-12-12 | |
| 2025-07-31 | 118.60K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-10-29 | 118.60K shares derived: sum of 2 quarters · filed 2025-10-29 | 473.51K shares 10-K · filed 2025-10-29 | |
| 2025-04-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-06-11 | 354.92K shares 10-Q · filed 2025-06-11 | ||
| 2025-01-31 | 354.92K shares 10-Q · filed 2025-03-14 | |||
| 2024-07-31 | 159.02K shares derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-12-20 | 159.02K shares derived: sum of 2 quarters · filed 2024-12-20 | 260.42K shares derived: sum of 3 quarters · filed 2024-12-20 | 506.83K shares 10-K/A · filed 2024-12-20 |
| 2024-04-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-06-14 | 101.40K shares derived: sum of 2 quarters · filed 2024-06-14 | 347.81K shares 10-Q · filed 2024-06-14 | 347.81K shares derived: sum of 4 quarters · filed 2024-12-20 |
| 2024-01-31 | 101.40K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-03-14 | 347.81K shares 10-Q · filed 2024-03-14 | 347.81K shares derived: sum of 3 quarters · filed 2024-12-20 | 347.81K shares derived: sum of 4 quarters · filed 2024-12-20 |
| 2023-10-31 | 246.41K shares 10-Q · filed 2023-12-14 | 246.41K shares derived: sum of 2 quarters · filed 2024-12-20 | 246.41K shares derived: sum of 3 quarters · filed 2024-12-20 | |
| 2023-07-31 | 0.00 shares derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-12-20 | 0.00 shares derived: sum of 2 quarters · filed 2024-12-20 | 220.02K shares 10-K/A · filed 2024-12-20 | |
| 2023-04-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-06-13 | 220.02K shares 10-Q · filed 2023-06-13 | ||
| 2023-01-31 | 220.02K shares 10-Q · filed 2023-03-14 | |||
| 2022-07-31 | 454.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-30 | 1.44M shares derived: sum of 2 quarters · filed 2023-10-30 | 1.51M shares derived: sum of 3 quarters · filed 2023-10-30 | 1.53M shares 10-K · filed 2023-10-30 |
| 2022-04-30 | 987.54K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-06-14 | 1.05M shares derived: sum of 2 quarters · filed 2022-06-14 | 1.08M shares 10-Q · filed 2022-06-14 | 1.99M shares derived: sum of 4 quarters · filed 2022-10-31 |
| 2022-01-31 | 63.36K shares derived: 10-Q 6 month − 10-Q/A 3 month · filed 2022-03-17 | 91.27K shares 10-Q · filed 2022-03-17 | 1.00M shares derived: sum of 3 quarters · filed 2022-10-31 | 1.00M shares derived: sum of 4 quarters · filed 2022-10-31 |
| 2021-10-31 | 27.91K shares 10-Q/A · filed 2022-02-28 | 940.15K shares derived: sum of 2 quarters · filed 2022-10-31 | 940.15K shares derived: sum of 3 quarters · filed 2022-10-31 | 974.87K shares derived: sum of 4 quarters · filed 2022-10-31 |
| 2021-07-31 | 912.25K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-10-31 | 912.25K shares derived: sum of 2 quarters · filed 2022-10-31 | 946.96K shares derived: sum of 3 quarters · filed 2022-10-31 | 956.32K shares 10-K · filed 2022-10-31 |
| 2021-04-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-06-14 | 34.71K shares derived: sum of 2 quarters · filed 2021-06-14 | 44.07K shares 10-Q · filed 2021-06-14 | 44.07K shares derived: sum of 4 quarters · filed 2021-10-18 |
| 2021-01-31 | 34.71K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-03-17 | 44.07K shares 10-Q · filed 2021-03-17 | 44.07K shares derived: sum of 3 quarters · filed 2021-10-18 | 47.28K shares derived: sum of 4 quarters · filed 2021-10-18 |
| 2020-10-31 | 9.36K shares 10-Q · filed 2020-12-15 | 9.36K shares derived: sum of 2 quarters · filed 2021-10-18 | 12.57K shares derived: sum of 3 quarters · filed 2021-10-18 | 28.43K shares derived: sum of 4 quarters · filed 2021-10-18 |
| 2020-07-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-10-18 | 3.21K shares derived: sum of 2 quarters · filed 2021-10-18 | 19.07K shares derived: sum of 3 quarters · filed 2021-10-18 | 24.07K shares 10-K · filed 2021-10-18 |
| 2020-04-30 | 3.21K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-06-09 | 19.07K shares derived: sum of 2 quarters · filed 2020-06-09 | 24.07K shares 10-Q · filed 2020-06-09 | 27.24K shares derived: sum of 4 quarters · filed 2020-10-29 |
| 2020-01-31 | 15.86K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-03-05 | 20.86K shares 10-Q · filed 2020-03-05 | 24.03K shares derived: sum of 3 quarters · filed 2020-10-29 | 24.78K shares derived: sum of 4 quarters · filed 2020-10-29 |
| 2019-10-31 | 5.00K shares 10-Q · filed 2019-12-09 | 8.17K shares derived: sum of 2 quarters · filed 2020-10-29 | 8.92K shares derived: sum of 3 quarters · filed 2020-10-29 | |
| 2019-07-31 | 3.17K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-10-29 | 3.92K shares derived: sum of 2 quarters · filed 2020-10-29 | 74.64K shares 10-K · filed 2020-10-29 | |
| 2019-04-30 | 750.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-06-05 | 71.47K shares 10-Q · filed 2019-06-05 | ||
| 2019-01-31 | 70.72K shares 10-Q · filed 2019-03-12 | |||
| 2018-07-31 | 4.00K shares 10-K · filed 2018-10-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |